Amgen (AMGN) presents positive top-line results from the Phase 3 MINT trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Goldman Sachs Reiterates Conviction Buy Rating on Amgen (AMGN)
October 16, 2024 6:02 AM EDTGoldman Sachs analyst Salveen Richter reiterated a Conviction Buy rating and $369.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "While AMGN continues to execute through a catalyst-rich year, the focus remains on key upcoming Ph2 obesity data for MariTide (GLP1-R agonistAn agonist is a drug that binds to a receptor and amplifies its intended effect./GIPR antagonist), expected by YE24, where positive results could unlock access to the obesity mega-TAM... More
